At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 38 enrolled
Drug / intervention
Prevacid +1 moredrug
Likely dose
Prevacid 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Do Laryngeal Biopsy Findings Predict Treatment Response in Suspected Laryngopharyngeal Reflux
In Brief
A Phase 4 clinical trial evaluating Prevacid and Esophageal and Laryngeal Biopsies for Larynx Disease and Gastroesophageal Reflux. Completed, enrolled 38 participants across 1 site.
Detailed Summary
The purpose of the study is to determine if tissue changes are predictor of clinical response to therapy. The hypothesis is that the patients who have laryngeal signs and symptoms related to acid reflux, will have ultrastructural changes on a laryngeal biopsy which are predictors of response to therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLarynx Disease, Gastroesophageal Reflux
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedMar 2007
Primary CompletionMar 2009
Study CompletionDec 2009
TodayJul 2026
First PostedMar 7, 2007
Enrollment StartMar 1, 2007
Primary CompletionMar 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 19.3 years ago
Interventions
Prevaciddrug
30 mg bid for 3 months
Esophageal and Laryngeal Biopsiesprocedure
repeat egd with biopsy after Prevacid 30 mg bid for 3 months